Biological Trace Element Research

, Volume 189, Issue 1, pp 145–156 | Cite as

Protective Effect of Nanoceria on Cisplatin-Induced Nephrotoxicity by Amelioration of Oxidative Stress and Pro-inflammatory Mechanisms

  • Mohd Aslam Saifi
  • Swetha Sangomla
  • Amit Khurana
  • Chandraiah GoduguEmail author


Cisplatin (CP) is one of the most important anticancer compounds with its therapeutic usefulness in diverse types of solid cancer. However, its use is limited due to nephrotoxicity induced by it. Oxidative stress is an effective participant which contributes actively to pathogenesis of CP-induced nephrotoxicity. Nanoparticle form of a rare earth metal cerium, also known as nanoceria (NC), has come up as a potential antioxidant and anti-inflammatory agent. In the present study, administration of CP in Swiss mice resulted in reduction of body weight, increased oxidative stress and pro-inflammatory cytokine levels including IL-6 and TNF-α along with alteration in normal histological architecture of kidney. On the contrary, NC (0.2 and 2 mg/kg i.p.) ameliorated nephrotoxicity of CP which was evident by reduction in levels of renal injury markers in plasma, i.e., creatinine and blood urea nitrogen. NC ameliorated oxidative stress by showing a reduction in levels of malondialdehyde and increased levels of endogenous antioxidants reduced glutathione and catalase. Further, NC treatment also reduced the levels of pro-inflammatory cytokines. Furthermore, protective effect of NC was also corroborated by histopathological studies wherein, kidneys from CP group showed altered tissue structure after acute as well as chronic exposure of CP while the tissues from treated groups showed absence of alterations in kidney histology. The results from present study suggested that oxidative stress and pro-inflammatory cytokines play a central role in pathogenesis of CP-induced nephrotoxicity and NC provides protection from CP-induced nephrotoxicity due to its antioxidant and anti-inflammatory properties.


Cisplatin Nephrotoxicity Nanoceria Oxidative stress Inflammation 


  1. 1.
    Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307–320Google Scholar
  2. 2.
    Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93–130Google Scholar
  3. 3.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279Google Scholar
  4. 4.
    Heiger-Bernays WJ, Essigmann JM, Lippard SJ (1990) Effect of the antitumor drug cis-diamminedichloroplatinum (II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29(36):8461–8466Google Scholar
  5. 5.
    Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin− DNA adducts. Chem Rev 99(9):2467–2498Google Scholar
  6. 6.
    Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007Google Scholar
  7. 7.
    Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota H-J, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167(6):1477–1484Google Scholar
  8. 8.
    Kuhlmann M, Burkhardt G, Köhler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12(12):2478–2480Google Scholar
  9. 9.
    Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223–242Google Scholar
  10. 10.
    Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A (2005) Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212(2–3):116–123Google Scholar
  11. 11.
    de Oliveira Mora L, Antunes LMG, Bianchi MdLP (2003) The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats. Pharmacol Res 47(6):517–522Google Scholar
  12. 12.
    Bompart G (1989) Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. Toxicol Lett 48(2):193–199Google Scholar
  13. 13.
    Jin-Gang Z, Lindup WE (1993) Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45(11):2215–2222Google Scholar
  14. 14.
    Hannemann J, Baumann K (1988) Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 51(2–3):119–132Google Scholar
  15. 15.
    Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14(7):2101–2112Google Scholar
  16. 16.
    Foster-Nora JA, Siden R (1997) Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm 54(7):787–800Google Scholar
  17. 17.
    Hartmann JT, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C (2000) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Investig New Drugs 18(3):281–289Google Scholar
  18. 18.
    Castiglione F, Dalla AM, Porcile G (1999) Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 85(2):85–91Google Scholar
  19. 19.
    Ramnath N, LoRusso P, Simon M, Martino S (1997) Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 20(4):368–372Google Scholar
  20. 20.
    Rick O, Beyer J, Schwella N, Schubart H, Schleicher J, Siegert W (2001) Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 12(8):1151–1155Google Scholar
  21. 21.
    Kyosseva SV, Chen L, Seal S, McGinnis JF (2013) Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice. Exp Eye Res 116:63–74Google Scholar
  22. 22.
    Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM (2009) Anti-inflammatory properties of cerium oxide nanoparticles. Small 5(24):2848–2856Google Scholar
  23. 23.
    Celardo I, Traversa E, Ghibelli L (2011) Cerium oxide nanoparticles: a promise for applications in therapy. J Exp Ther Oncol 9(1):47–51Google Scholar
  24. 24.
    Das M, Patil S, Bhargava N, Kang J-F, Riedel LM, Seal S, Hickman JJ (2007) Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials 28(10):1918–1925Google Scholar
  25. 25.
    González-Flores D, De Nicola M, Bruni E, Caputo F, Rodríguez AB, Pariente JA, Ghibelli L (2014) Nanoceria protects from alterations in oxidative metabolism and calcium overloads induced by TNFα and cycloheximide in U937 cells: pharmacological potential of nanoparticles. Mol Cell Biochem 397(1–2):245–253Google Scholar
  26. 26.
    Pirmohamed T, Dowding JM, Singh S, Wasserman B, Heckert E, Karakoti AS, King JE, Seal S, Self WT (2010) Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem Commun 46(16):2736–2738Google Scholar
  27. 27.
    Korsvik C, Patil S, Seal S, Self WT (2007) Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem Commun 10:1056–1058Google Scholar
  28. 28.
    Dowding JM, Dosani T, Kumar A, Seal S, Self WT (2012) Cerium oxide nanoparticles scavenge nitric oxide radical (˙ NO). Chem Commun 48(40):4896–4898Google Scholar
  29. 29.
    Cimini A, D’Angelo B, Das S, Gentile R, Benedetti E, Singh V, Monaco AM, Santucci S, Seal S (2012) Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater 8(6):2056–2067Google Scholar
  30. 30.
    Estevez A, Pritchard S, Harper K, Aston J, Lynch A, Lucky J, Ludington J, Chatani P, Mosenthal W, Leiter J (2011) Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radic Biol Med 51(6):1155–1163Google Scholar
  31. 31.
    Heckman KL, DeCoteau W, Estevez A, Reed KJ, Costanzo W, Sanford D, Leiter JC, Clauss J, Knapp K, Gomez C (2013) Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. ACS Nano 7(12):10582–10596Google Scholar
  32. 32.
    Sangomla S, Saifi MA, Khurana A, Godugu C (2018) Nanoceria ameliorates doxorubicin induced cardiotoxicity: possible mitigation via reduction of oxidative stress and inflammation. J Trace Elem Med Biol 47:53–62Google Scholar
  33. 33.
    Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE (2007) Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc Res 73(3):549–559Google Scholar
  34. 34.
    Pourkhalili N, Hosseini A, Nili-Ahmadabadi A, Rahimifard M, Navaei-Nigjeh M, Hassani S, Baeeri M, Abdollahi M (2012) Improvement of isolated rat pancreatic islets function by combination of cerium oxide nanoparticles/sodium selenite through reduction of oxidative stress. Toxicol Mech Methods 22(6):476–482Google Scholar
  35. 35.
    Khurana A, Saifi M, Godugu C (2017) Nanoceria reduces oxidative stress, inflammation and display anti-fibrotic properties in animal models of chronic pancreatitis. Pancreas, Lippincott Williams & Wilkins Two Commerce SQ, 2001 Market St, Philadelphia, PA 19103 USA, pp 1411–1412Google Scholar
  36. 36.
    Asati A, Santra S, Kaittanis C, Perez JM (2010) Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano 4(9):5321–5331Google Scholar
  37. 37.
    Sack M, Alili L, Karaman E, Das S, Gupta A, Seal S, Brenneisen P (2014) Combination of conventional chemotherapeutics with redox-active cerium oxide nanoparticles—a novel aspect in cancer therapy. Mol Cancer Ther 13(7):1740–1749Google Scholar
  38. 38.
    Tarnuzzer RW, Colon J, Patil S, Seal S (2005) Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett 5(12):2573–2577Google Scholar
  39. 39.
    Xu M-X, Zhu Y-F, Chang H-F, Liang Y (2016) Nanoceria restrains PM2. 5-induced metabolic disorder and hypothalamus inflammation by inhibition of astrocytes activation related NF-κB pathway in Nrf2 deficient mice. Free Radic Biol Med 99:259–272Google Scholar
  40. 40.
    Reddy DR, Khurana A, Bale S, Ravirala R, Reddy VSS, Mohankumar M, Godugu C (2016) Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. SpringerPlus 5(1):1618Google Scholar
  41. 41.
    Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta Gen Subj 582(1):67–78Google Scholar
  42. 42.
    Aebi H (1984) [13] Catalase in vitro. Methods Enzymol 105:121–126Google Scholar
  43. 43.
    Kumar GS, Kulkarni A, Khurana A, Kaur J, Tikoo K (2014) Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem Biol Interact 223:125–133Google Scholar
  44. 44.
    Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8(5):368–379Google Scholar
  45. 45.
    Gong J, Costanzo A, Yang H-Q, Melino G, Kaelin WG, Levrero M, Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399(6738):806–809Google Scholar
  46. 46.
    Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48(3):761–770Google Scholar
  47. 47.
    Antunes LMG, Darin JDAC, Maria de Lourdes PB (2001) Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43(2):145–150Google Scholar
  48. 48.
    Santos N, Catao C, Martins N, Curti C, Bianchi M, Santos A (2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81(7):495–504Google Scholar
  49. 49.
    Cummings BS, Schnellmann RG (2002) Cisplatin-induced renal cell apoptosis: caspase 3-dependent and-independent pathways. J Pharmacol Exp Ther 302(1):8–17Google Scholar
  50. 50.
    Zhang B, Ramesh G, Norbury C, Reeves W (2007) Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells. Kidney Int 72(1):37–44Google Scholar
  51. 51.
    Baliga R, Ueda N, Walker PD, Shah SV (1999) Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31(4):971–997Google Scholar
  52. 52.
    Ramesh G, Reeves WB (2004) Inflammatory cytokines in acute renal failure. Kidney Int 66:S56–S61Google Scholar
  53. 53.
    Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int 65(2):490–498Google Scholar
  54. 54.
    Antunes LMG, Darin JDAC, Bianchi MDLP (2000) Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 41(4):405–411Google Scholar
  55. 55.
    Alili L, Sack M, Karakoti AS, Teuber S, Puschmann K, Hirst SM, Reilly CM, Zanger K, Stahl W, Das S (2011) Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor–stroma interactions. Biomaterials 32(11):2918–2929Google Scholar
  56. 56.
    Lin W, Huang Y-w, Zhou X-D, Ma Y (2006) Toxicity of cerium oxide nanoparticles in human lung cancer cells. Int J Toxicol 25(6):451–457Google Scholar
  57. 57.
    Alili L, Sack M, von Montfort C, Giri S, Das S, Carroll KS, Zanger K, Seal S, Brenneisen P (2013) Downregulation of tumor growth and invasion by redox-active nanoparticles. Antioxid Redox Signal 19(8):765–778Google Scholar
  58. 58.
    Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17(10):1195–1214Google Scholar
  59. 59.
    Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239–247Google Scholar
  60. 60.
    Kumari P, Saifi MA, Khurana A, Godugu C (2018) Cardioprotective effects of nanoceria in a murine model of cardiac remodeling. J Trace Elem Med Biol 50:198–208Google Scholar
  61. 61.
    Ramesh G, Reeves WB (2002) TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110(6):835–842Google Scholar
  62. 62.
    Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12(6):738–747Google Scholar
  63. 63.
    Saifi MA, Khurana A, Godugu C (2018) Nanomaterials in chromatography: current trends in chromatographic research technology and techniques. In: Nanotoxicology: toxicity and risk assessment of nanomaterials, nanomaterials in chromatography. Elsevier, Amsterdam, pp 437–465Google Scholar
  64. 64.
    Saifi M, Khan W, Godugu C (2018) Cytotoxicity of nanomaterials: nanotoxicology to address the safety concerns of nanoparticles. Pharm Nanotechnol 6(1):3–16Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Regulatory ToxicologyNational Institute of Pharmaceutical Education and Research (NIPER)HyderabadIndia

Personalised recommendations